The PP2A signaling pathway is a druggable target in murine and human hepatocellular carcinoma

Background: Hepatocellular carcinoma (HCC) is one of the most common solid tumor entities worldwide and the third leading cause of cancer related death. For advanced stage disease, systemic pharmacotherapy is the only established therapy, targeting the oncogene protein kinases pathways. However, chemotherapy still yields poor response rates and survival in those patients. Recently, it could be demonstrated, that activating the protein phosphatase pathways may have a therapeutic impact on various types of cancer. Methods: The murine and human HCC cell lines Hepa 1–6, Hepa 129, HuH7, HepG2 and Hep3B were used for…